Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, August 5 at 2:00 PM EDT

Register Free →

Get CLEATUSFree Trial

Get CLEATUSFree Trial

Search

Top

PPD DEVELOPMENT, L.P. Wilmington NC USA

UEI: SLED_DEE7F742FCED79A9

PPD DEVELOPMENT, L.P. Wilmington NC USA is a federal contractor, registered under UEI SLED_DEE7F742FCED79A9. It has been awarded $13,580,947 across 2 federal contracts. Primary work spans Research and Development in Biotechnology (except Nanobiotechnology) and Unknown NAICS. Top awarding agencies include Aspr Barda Division Contracts Management & Acq and Aspr Administration For Strategic Preparedness And Response.

Contact Information

Registration and classification details

Registration

UEI Code

SLED_DEE7F742FCED79A9

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

Aspr Barda Division Contracts Management & Acq$12.8M94.5%

Aspr Administration For Strategic Preparedness And Response$750.0K5.5%

Awards by NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)$12.8M94.5%

- Unknown NAICS$750.0K5.5%

Awards by Agency Over Time

Awards by Place of Performance

Open opportunities in PPD DEVELOPMENT, L.P. Wilmington NC USA's top NAICS codes and agencies

Humanized Antibody Library Screening and Transferrin Receptor DevelopmentThe contract involves the customized screening of a humanized antibody library to develop a functional transferrin receptor, encompassing molecular design, in vitro selection, and optimization of binding affinity and specificity. The work requires advanced techniques in antibody engineering to identify and refine candidates capable of high-affinity, selective interaction with the transferrin receptor, with the goal of producing a therapeutically viable candidate. The scope includes iterative cycles of library screening, functional characterization, and structural optimization to enhance target binding while minimizing off-target interactions, ensuring the final product meets stringent performance benchmarks. This subcontract is issued under the NAICS code 541714 for research and development in the biological sciences and is associated with the National Institutes of Health through the Department of Health and Human Services. The place of performance is in Bethesda, Maryland, with a deadline for proposals set for July 31, 2026. The contract is expected to support biomedical innovation targeting receptor-mediated delivery systems and requires expertise in molecular biology, high-throughput screening, and protein engineering. No specific set-aside provisions are indicated, and the work is open to qualified subcontractors capable of delivering scalable, data-driven antibody development solutions within the defined timeline.

National Institutes Of Health Olao

POSTED

DEADLINE

Recombinant Antibody Discovery & Engineering ServicesThe contract involves the discovery, humanization, and engineering of single domain antibodies designed to penetrate the blood-brain barrier using phage and yeast display platforms. This effort includes advanced antibody optimization through affinity maturation to enhance binding strength and specificity, as well as comprehensive stability testing to ensure functional integrity under physiological conditions. The work is scientifically focused on developing recombinant antibody formats capable of crossing the blood-brain barrier, a critical step for therapeutic applications targeting neurological diseases. This subcontract, issued by the National Institutes of Health under the Department of Health and Human Services, is classified under NAICS code 541714 for research and development in the physical, engineering, and life sciences. The opportunity was posted on July 24, 2026, with a response deadline of August 3, 2026. Performance is expected to take place in Bethesda, Maryland, 20892. The project does not specify a set-aside type or point of contact details, and the full solicitation can be accessed via the provided SAM.gov link for additional procedural or submission guidelines.

National Institutes Of Health Olao

POSTED

DEADLINE

Bioinformatics and Data Analysis for Biomarker ResearchThe contract titled Bioinformatics and Data Analysis for Biomarker Research seeks to deliver computational analysis of high-throughput sequencing data with the goal of identifying and validating biomarker signatures, accompanied by the generation of detailed research reports. This effort is classified as a subcontract under NAICS code 541714 and is managed by the Department of Veterans Affairs through its 245-NETWORK Contract Office 5. The work is to be performed at a location in Washington, D.C., with a zip code of 20422. The opportunity was posted on July 24, 2026, and responses are due by August 7, 2026, at 5:00 PM EST. Although no specific set-aside designation is indicated, the contract is structured to support advanced bioinformatics capabilities essential for translational research in biomarker discovery.

245-NETWORK Contract Office 5 (36C245)

POSTED

DEADLINE

Develop and Validate Transferrin ReceptorThe National Institutes of Health, under the Department of Health and Human Services, has issued a presolicitation notice for the development and validation of a transferrin receptor, identified by solicitation number 75N98026Q00866. This opportunity is open for responses until July 31, 2026, and was posted on July 24, 2026, with no set-aside provisions applied, making it open to all eligible entities. The work will be performed in Bethesda, Maryland, and falls under the NAICS code 541714, which corresponds to research and development in the physical, engineering, and life sciences. The primary point of contact for inquiries is Towanda Daniels, reachable via email at danielt@mail.nih.gov. Interested parties are directed to the official SAM.gov workspace link for further details and submission guidelines. The contract aims to support advanced scientific research focused on the transferrin receptor, likely to advance biomedical applications or therapeutic technologies. All proposals must adhere to the requirements outlined in the notice of intent, and submissions should be prepared with consideration for the technical scope, timeline, and performance standards expected by the NIH Office of Laboratory Animal Welfare. The contract is structured to enable innovation in molecular biology or drug delivery systems involving receptor targeting, with performance expected within the confines of federal research protocols and compliance standards.

National Institutes Of Health Olao

POSTED

DEADLINE

Humanized single domain antibodies for therapeutic brain deliveryThe National Institutes of Health Office of Extramural Research, under the Department of Health and Human Services, has issued a presolicitation for the development of humanized single domain antibodies designed for therapeutic delivery across the blood-brain barrier. The project, identified by solicitation number 75N98026Q00867, aims to advance novel antibody technologies capable of targeting brain-specific pathologies with enhanced precision and efficacy. All responses are due by August 3, 2026, and no set-aside provisions are applicable, meaning the opportunity is open to all eligible entities. The performance location is designated as Bethesda, Maryland, with the contract administration handled by the agency’s office at 20892. Primary point of contact for inquiries is Towanda Daniels, reachable via email at danielt@mail.nih.gov. The solicitation was posted on July 24, 2026, and all potential offerors are directed to the designated SAM.gov workspace for additional details and documentation. No NAICS code has been assigned at this stage, and the initiative reflects a strategic effort to enable breakthrough treatments for neurological disorders through innovative biotherapeutic platforms. Applicants must ensure full compliance with the requirements outlined in the attached Notice of Intent.

National Institutes Of Health Olao

POSTED

DEADLINE

Notice of Intent to Award a Sole Source Contract – Sequencing Bundibugyo virus disease (BDBV) in the 2026 outbreakThe Food and Drug Administration is planning to award a sole source firm-fixed price purchase order to The University of Liverpool under simplified acquisition procedures for the sequencing of Bundibugyo virus disease during the 2026 outbreak, relying on FAR Part 6.103-1 which permits non-competitive procurement when only one responsible source exists. This action falls under the NAICS code 541714 for Research and Development in Biotechnology and is not open for competitive bidding, as the FDA has determined that The University of Liverpool is the only entity with the necessary expertise and capacity to meet the technical requirements for this highly specific viral sequencing effort. The contract is intended to support bioanalytical method development and sample analysis by providing critical reagents and reference standards for quantifying CYP enzyme substrates and metabolites in hepatocyte experiments during the outbreak response. Responses to this notice must be submitted by Ryan Alexander at ryan.alexander@fda.hhs.gov no later than 5:00 pm on July 29, 2026, and must include a detailed capability statement for any other organization seeking consideration, though the government retains full discretion to determine whether a response justifies competitive solicitation. The procurement is not a request for competitive quotes, and no set-aside is being applied. The contract will be administered from the FDA’s office in Rockville, Maryland, with performance primarily occurring in Liverpool, England, and the solicitation number is OC-2026-135667, issued on July 24, 2026.

Food And Drug Administration

POSTED

DEADLINE

Procurement of lateral flow (LFA) strips for the rapid HIV nucleic acid diagnostic testThe Centers for Disease Control and Prevention is soliciting bids for the procurement of 4,000 lateral flow strips intended for use in a rapid HIV nucleic acid diagnostic test under a firm-fixed-price contract, issued as a Request for Quote in accordance with FAR Subpart 12 for commercial items. The solicitation number is 75D30126Q79099, with a performance period of August 1, 2026, to December 31, 2026, and an option to extend services for up to six additional months. Proposals must be submitted electronically to Eugene Gutierrez at zvm0@cdc.gov no later than 3:00 P.M. Eastern Standard Time on Friday, July 24, 2026, with no telephonic or paper submissions accepted. The place of performance is the CDC facility at 1600 Clifton Road, Building 17, Atlanta, GA 30329-4018. Offerors must be registered in the System for Award Management at the time of submission and are required to comply with all applicable FAR clauses, including 52.212-1 and 52.212-4, along with deviations such as those addressing trafficking in persons, contractor employee whistleblower rights, sustainable products and services, Buy American Act alternatives for Israeli and Korean end products, and prohibitions on unauthorized information sharing. Technical evaluation is the predominant factor in award, emphasizing experience with biomedical devices, FDA approval processes, and prior work with lateral flow technology, with price considered secondary. The contractor must deliver 200 prototype strips and 4,000 final units meeting stringent performance standards: ≤0.5% false positive rate and ≤1% false negative rate using CDC’s LAMP reaction, and must ensure full compatibility with CDC’s mass production protocols. All deliverables must conform to Section 508 accessibility requirements, including WCAG 2.0 Level AA, and vendors must provide a Voluntary Product Accessibility Template or HHS conformance checklist. The contract imposes strict security and confidentiality obligations, including mandatory non-disclosure agreements for all employees accessing sensitive information, identification protocols to distinguish contractor personnel from government staff, and prohibitions against retaining or disseminating federal records or Privacy Act data. Subcontractors must be bound by the same requirements, and all payments must be processed via the Treasury’s Invoice Processing Platform using an ACH Vendor Enrollment

CDC Office Of Acquisition Services

POSTED

DEADLINE

Illumina Reagent KitsThe United States Department of the Naval Medical Research Command intends to award a sole source contract to Illumina, Inc. of San Diego, California, for the purchase of Illumina Reagent Kits. This procurement is not a competitive solicitation, but responses received will be considered if submitted. The action is classified under NAICS code 541714 and will be conducted under FAR Part 12 guidelines for commercial items. All vendors must be registered in the Systems for Award Management (SAM) and possess a Unique Entity Identification Number (UEI) to be eligible for award, with SAM registration available free of charge through sam.gov or by calling (866) 606-8220. The contract is identified by solicitation number 1301397256, posted on July 23, 2026, with a response deadline of August 7, 2026. The contracting office is located in Silver Spring, Maryland, with performance expected in Frederick, Maryland. Primary point of contact is Shamai Carter, reachable at shamai.m.carter.civ@health.mil, with Nataki Johnson as the secondary contact.

Naval Medical Research Center

POSTED

DEADLINE

Battlefield Pain Management – AnalgesicThis solicitation under the prototype Other Transaction Authority (10 U.S.C. 4022) seeks the development of a single-use analgesic product for acute moderate to severe battlefield pain, with the ultimate goal of obtaining FDA approval. The product must be a combination drug-device system—such as a nasal spray or autoinjector—that is rapid to administer, compact for individual carry, and stable under extreme environmental conditions, capable of withstanding temperature excursions between -25°C and 45°C without refrigeration and maintaining a 2-3 year shelf life at controlled room temperature. It must comply with USP <659> packaging and storage standards, adhere to 21 CFR Part 820 quality system regulations for labeling and control, and meet strict physiological limits including no more than a 20% reduction in baseline blood pressure, heart rate, or blood clotting ability. The product must be classified as a DEA Schedule II or higher controlled substance and must not require special handling for humidity, pressure, or temperature, verified through MIL-STD-810 testing. The effort spans an estimated eight-year period, divided into three sequential objectives: three years for Chemistry, Manufacturing, and Controls (CMC) and stability studies; two years for non-clinical enabling studies; and three years for clinical trials and human factors testing, including potential Emergency Use Authorization (EUA) submission. Deliverables include detailed regulatory documentation, study strategies, interim and final reports, regulatory meeting minutes, protocol approvals from IACUC and ORRC, and full compliance with Controlled Unclassified Information (CUI) marking and data handling protocols. The contract does not fall under FAR or DFARS, but incorporates selected clauses for electronic payment submission, government property management, and termination for convenience. Proposals must be submitted in three volumes—Technical, Management, and Administrative and Cost—with the technical volume limited to 20 pages plus an unlimited attachment for the Statement of Work. A key eligibility requirement is a pass/fail gate: the proposal must demonstrate participation of at least one nontraditional defense contractor or nonprofit research institute, or that all significant participants are small businesses or nontraditional contractors, or that at least one-third of the total project cost is funded by non-federal sources. The proposal deadline has been extended to August 14, 2026, with all submissions required via email in searchable PDF format, compatible with Microsoft Office and Adobe Acrobat, and free of malware, passwords, or hyperlinks.

Defense Health Agency

POSTED

DEADLINE

Development of Light-Responsive Artificial Cells using Plant-Based Photoreceptor SystemsThe United States Army Corps of Engineers Engineer Research and Development Center Construction Engineering Research Laboratory is seeking to develop light-responsive artificial cells by integrating plant-derived UVR8 photoreceptor systems into synthetic biology platforms, using high-throughput protein engineering and AI-assisted structural refinement to create programmable, pseudo-living systems activated by environmental light stimuli. The project aims to advance foundational science in synthetic biology by leveraging Bioconscientia, LLC’s uniquely specialized expertise in UVR8 photoreceptor technology, which enables precise sensing of UV-B light in a manner unmatched by other entities. Due to the highly specialized nature of the required research and Bioconscientia’s irreplaceable knowledge of existing experimental data and technical pathways, the government intends to award a sole-source contract to this vendor under RFO FAR 12.102(a), with an anticipated award date of September 30, 2026. This presolicitation notice, issued under FAR Part 5.101(a) with solicitation number W9132T26QA015 and NAICS code 541714, does not constitute a formal request for proposals or a competitive procurement, nor is it a set-aside. Interested parties may submit capability statements to CERL-CT-QUOTES@USACE.ARMY.MIL by July 31, 2026, to be reviewed for potential technical equivalency, but submission does not guarantee a change to the government’s acquisition strategy. The government retains full discretion to proceed with sole-source award regardless of responses received. All work will be performed in Champaign, Illinois, and the primary point of contact for submissions is Lurline L. Simmons, with Andrea J. Thomas serving as the contracting officer. No telephone inquiries will be accepted.

W2R2 Construction Engrg Labor

POSTED

DEADLINE

AI/ML and Data Analytics for Cardiovascular Device Validation

FDA Office Of Acq Grant Svcs

POSTED

DEADLINE

Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)The Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) is soliciting collaborative participation through a continuous, open Participant Basic Agreement (PBA) under the HEALER portfolio to advance next-generation, threat-agnostic host-directed therapeutics designed to enhance physiological resilience against CBRN threats. This initiative targets five critical biological systems—neurological protection, respiratory stabilization, immune modulation, hematologic and vascular function, and cellular stress and repair pathways—with the goal of developing dual-use medical countermeasures that serve both military and civilian critical care needs. The program invites two categories of collaborators: therapeutic developers with candidates that modulate host response mechanisms and drug development support providers including CROs and CDMOs with capabilities in preclinical testing, clinical trial execution, cGMP manufacturing, regulatory strategy, and advanced modeling. Submission requires a white paper of no more than five pages excluding a cover page, detailing product mechanism of action, efficacy data from validated animal models, regulatory status such as IND experience and clinical trial history, manufacturing capacity and scale-up plans, and company profile for therapeutic developers, or core capabilities and infrastructure for service providers. All participants must express willingness to collaborate with other PBA holders to foster an integrated development ecosystem. The solicitation, issued under statutory authority of 10 U.S.C. §§4021–4023, operates outside the Competition in Contracting Act and does not follow traditional procurement or evaluation frameworks, eliminating standard contract clauses, formal evaluation factors, pricing structures, or submission deadlines. Instead, awards are made at the government’s discretion through a non-traditional acquisition mechanism designed to accelerate innovation. Technical and administrative inquiries are directed to Hunter Robinson and Alexander Mayatte at the U.S. Army’s Aberdeen Proving Ground, Maryland office. Participation prerequisites include current registration in the System for Award Management (SAM), compliance with FDA regulatory pathways, and adherence to cGMP standards for manufacturing. While no specific delivery dates, FOB terms, inspection criteria, or cost estimates are defined, performance is expected to align with the mission of CPE CBRND to enable the Joint Force to operate effectively in CBRN-contested environments. Intellectual property considerations, teaming arrangements, and the scalability of therapeutic candidates are central to selection, with no socioeconomic or size status certifications required. The structure prioritizes agility, collaboration, and cross-sector innovation over rigid compliance, enabling a dynamic pipeline of medical countermeasures capable of addressing evolving biological threats through sustained host resilience.

POSTED

DEADLINE

Non-Optical Methods for High Speed Protein ControlDARPA’s Biological Technologies Office is seeking innovative solutions through the ERIS Marketplace to develop a new class of rapidly switchable, non-optogenetic protein domains capable of enabling real-time, massless control of cellular processes. The goal is to create a robust, modular molecular tool that responds to non-optical external signals such as magnetic fields or focused ultrasound, allowing precise regulation of protein function across cell membranes without relying on light or chemicals. Proposed solutions must achieve activation and deactivation kinetics of no more than two seconds, demonstrate reliable performance through at least 300 repetitive cycles in living cells, and function effectively in both split-protein dimerization and allosteric conformational configurations. This effort explicitly excludes any modifications or enhancements to existing optogenetic, light-based, or chemical systems. The anticipated contract value is $400,000 for a 12-month performance period, with awards being made on a rolling basis as solutions are evaluated, and the government reserves the right to issue awards before the December 8, 2026 submission deadline. Proposals must be submitted via the DARPA Connect ERIS Portal as a video that follows the required title format, or existing awardable solutions may be flagged for consideration by emailing ERIS@darpa.mil with specific subject and body requirements. Evaluation will focus on four core areas: a deep understanding of the problem space and current limitations in fields like sonogenetics and magnetogenetics, a significant technical leap in achieving rapid and repeatable protein control, demonstrated expertise in synthetic biology, protein engineering, and biophysics with a proven track record of quantitative in vivo characterization, and the potential of the solution to become a foundational tool in synthetic biology with broad applications in defense-relevant areas such as biomanufacturing, cell-based therapeutics, and biosensing. All submissions are subject to the ERIS assessment process, which serves as a mandatory pass/fail gate—only solutions deemed awardable by this process will be considered for BTO award. The procuring agency is the Department of Defense through DARPA’s Arlington, VA office, and all participants must comply with the ERIS Master Solicitation requirements available via SAM.gov.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Notice of Intent to Sole Source – University of Maryland Medical Center

National Institutes Of Health - Cc

POSTED

DEADLINE

Limited Competition: Clinical and Translational Science Awards (CTSA) Program: Collaborative and Innovative Acceleration AwardThe Congressionally mandated Clinical and Translational Science Awards (CTSA) Program aims to accelerate the translation of scientific discoveries into practical treatments, diagnostics, and health interventions that enhance patient and public health by funding a national network of academic medical centers. This network provides essential infrastructure, expertise, training, and collaborative platforms needed to move research from the laboratory into clinical practice and community health settings. The current opportunity is a forecast for a limited competition soliciting applications for the Collaborative and Innovative Acceleration Award, designed to support the development and implementation of novel approaches, technologies, or models that amplify the impact of translational research and expedite the delivery of effective therapies to all populations. Funding is authorized under Sections 301 and 405 of the Public Health Service Act, and governed by Federal Regulations 42 CFR Part 52 and 2 CFR Part 200. Eligible organizations may apply under this limited competition, and proposals will undergo standard National Institutes of Health peer review, with funding awarded only to meritorious applications. The announcement is issued by the National Institutes of Health, under the Department of Health and Human Services, with specific inquiries directed to the Division of Clinical Innovation at NCATS. The forecast was posted on July 20, 2026, and further details can be accessed through the official grants.gov listing, though no set-aside type, NAICS code, or specific place of performance is indicated.

National Institutes Of Health

POSTED

DEADLINE

On-Site Technical Deployment and Integration

FDA Office Of Acq Grant Svcs

POSTED

DEADLINE

Hypoxia Chamber ServicesNASA Johnson Space Center is soliciting offers for Hypoxia Chamber Services under solicitation number 80JSC026Q0008 to support research on the physiological, cognitive, and clinical effects of mild hypobaric hypoxia as part of the Artemis Program. The contract requires comprehensive services including infrastructure, personnel, training, materials, food, supplies, and operational support necessary to conduct controlled hypoxia experiments. This is a combined synopsis and solicitation issued under FAR Subpart 12.6, with no written solicitation to follow, and all information is contained within the posted notice and attachments, particularly Attachment A for the Performance Work Statement and Attachment D for additional submission requirements. The NAICS code is 541714 with a size standard of 1,000 employees, and offerors must self-certify their size status. Evaluation will prioritize Technical Acceptability and Past Performance as significantly more important than Price, though Price becomes increasingly relevant when proposals are closely matched in technical merit. All submissions must include completed representations and certifications per FAR 52.212-3 and comply fully with FAR 52.212-1 and 52.212-4. Proposals must be submitted electronically via email to the designated NASA contacts no later than 1:00 PM CST on August 24, 2026, with questions due by July 29, 2026. The Government assumes no responsibility for electronic submission failures, and late submissions will be rejected per FAR provisions. The place of performance is Houston, Texas, and the Ombudsman clause is applicable for dispute resolution.

NASA Johnson Space Center

POSTED

DEADLINE

Elucidation and Validation of the role of Transporters in the Placenta, Lactating Mammary Gland, Developing Gut, and Blood Brain BarrierThe Eunice Kennedy Shriver National Institute of Child Health and Human Development is advancing its mission to improve maternal, fetal, and child health by launching a second phase of the Transporter Elucidation Network, focused on understanding how biological transporters and local metabolic processes regulate exposure to nutrients, medications, microbiome-derived compounds, and environmental chemicals across critical perinatal barriers. This initiative will develop comprehensive multi-barrier frameworks that connect the maternal gut, placenta, lactating mammary epithelium, infant gut, and infant blood-brain barrier, building on prior organ-specific research to create standardized models, resources, and prototype multi-compartment systems that reflect the dynamic interplay of transporters, their polarity, kinetics, and biotransformation capacities during pregnancy, lactation, and infant development. The goal is to deepen mechanistic insights into how these systems influence nutrient delivery, drug distribution, and neurodevelopmental outcomes in early life. This phase will establish community-wide resources to support integrated studies of perinatal exposure, risk assessment, and targeted interventions across linked maternal-fetal-infant systems, while strengthening collaboration among researchers and accelerating the sharing of tools and data. Emphasis is placed on human-based and developmentally relevant models to ensure biological accuracy and translational impact. The effort also aims to cultivate a next-generation workforce skilled in transporter science, fostering innovation in pediatric pharmacology and neonatal health. Authorized under 42 U.S.C. § 241, the initiative is being led by the Obstetric and Pediatric Pharmacology and Therapeutics Branch of NICHD, with inquiries directed to their designated point of contact, and the opportunity was publicly forecasted on July 16, 2026.

National Institutes Of Health

POSTED

DEADLINE